Early promise for Enterome’s microbiome-derived cancer vaccine

Early data show Enterome’s microbiome-based cancer vaccine may have additive efficacy when used as part of a triplet combination to treat recurrent glioblastoma.

At the American Society of Clinical Oncology (ASCO) annual meeting, Enterome Bioscience S.A. presented data from the Phase I/II ROSALIE trial of therapeutic vaccine EO2401 either in combination with Opdivo nivolumab or in a triplet combo that adds Avastin bevacizumab. ...